Coagulation and Natural Anticoagulants » Coagulation Factors and Inhibitors

Abstract Number: PB0201

A Comparison of Mass and Potency Equated Bovine and Porcine Heparins

S. Krishnappan, F. Siddiqui, A. Farooqui, O. Iqbal, A. Kouta, D. Hoppensteadt, W. Jeske, J. Walenga, J. Fareed

Abstract Number: PB0189

A Double Heterozygous Factor VII (FVII) Deficiency: Exon 9 Missense Mutation (Arg364Gln – FVII Padua) and a Novel Exon 3 Missense Mutation (Ala87Gly)

C. Gallardo¹, C.L.L. Sum¹, L.J.L. Wong¹, K.H. Ong¹, L.L. Goh²

Abstract Number: PB0223

A Novel Coagulation Factor VIII with Reduced Immunogenicity

K. Winterling¹, W. Martin², A.S. De Groot², J. Daufenbach¹, J. Schüttrumpf³, S. Kistner¹

Abstract Number: PB0169

A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINs

W. Sanrattana¹, S. Smits¹, D. Monroe², C. Maas¹, S. de Maat¹

Abstract Number: PB0158

A Novel Rare C. – 39C>T Mutation in the PROS1 5’UTR Causes Protein S Deficiency by Creating a New Upstream Translation Initiation Codon and an Overlapping Open Reading frame

B. Jaspard-Vinassa¹, C. Proust^2,3, O. Soukarieh^2,3, C. Mouton⁴, Y. Huguelin⁴, M. Roux⁵, J. Constans⁶, A. Boland⁷, R. Olaso⁷, J.-F. Deleuze⁷, P.-E. Morange⁸, S. Labrouche-Colomer^1,4, D.-A. Trégouët^2,3, GENMED Consortium

Abstract Number: PB0224

A Sensitive and Specific Assay to Measure TF Activity in Cell-derived Extracellular Vesicles Based on Thrombin Generation

B. Østerud, N. Latysheva, O. Snir, J.-B. Hansen

Abstract Number: PB0162

Acquired Haemophilia Spanish Registry, First Five Years of Activity

M.E. Mingot-Castellano^1,2, J.M. Bastida-Bermejo³, S. Haya⁴, J. Pardos-Gea⁵, M.D.C. Fernandez-Sanchez de Mora⁶, R. Lluch⁷, R. Nuñez⁸, M.T. Alvarez-Roman⁹, I. Soto-Ortega¹⁰, J.M. Martín-Antoran¹¹, J.A. Rodriguez-Garcia¹², M. Carrasco-Exposito¹³, J.A. Rodriguez-Alen¹⁴, C. Cervero-Santiago¹⁵, M. Perez-Sanchez¹⁶, R. Rodriguez-Gonzalez¹⁷, N. Fernandez-Mosteirin¹⁸, M.N. Alonso-Escobar¹⁹, A. Moreto-Quintana²⁰, P. Marco-Vera²¹, Registro Español de Hemofilia Adquirida

Abstract Number: PB0154

Activated recombinant Factor VII (rFVIIa) Inhibitor in Iran: Immunogenicity is a Major Challenge through Treated Bleeds Covered with rFVIIa

P. Eshghi¹, M. Ahmadinejad², M. Karimi³

Abstract Number: PB0227

Addition of Histone Deacetylase Inhibitors Increases Recombinant Factor V Expression in BHK Cells

T. Petrillo¹, J.C. Small¹, R.M. Camire^1,2

Abstract Number: PB0239

Always Ask Relevant Questions to Patients Might Be They Tell You the Diagnosis

A. Naz¹, T. Masood², N. Saqlain³, N. Samad⁴, T. Shamsi⁵

Abstract Number: PB0226

Anti-factor V Inhibitor after Liver Transplantation

A. Ciavarella¹, A. Artoni¹, M. Capecchi¹, S. Bhoori², V. Mazzaferro², C. Novembrino¹, A. Cairo¹, M. Clerici¹, C. Valsecchi³, F. Peyvandi¹, I. Martinelli¹

Abstract Number: PB0213

Anticoagulant Effect of Novel Nanoparticles Functionalized with Synthetic Piperazinone Derivatives as FXa Inhibitors

J. Salazar^1,2, C. Rojas², F. Santana-Romo², A. Romero Bohorquez³, C. Vilos⁴, F. Zacconi^2,5

Abstract Number: PB0182

Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications

B. Daravath¹, J. Fareed¹, O. Iqbal¹, A. Kouta¹, D. Hoppensteadt¹, W. Jeske¹, F. Siddiqui¹, M. Lewis¹, B. Lewis²

Abstract Number: PB0166

Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model

M.A. Kurz¹, C.V. Pollack, Jr.¹, J.M. Connors², J.H. Levy³, C. Drummond⁴, D. Klein⁵, H.D. Josuns⁵, R. Pielemeier⁴, J. Buchino⁴, P. Osborne⁴, N.J. Hayward¹

Abstract Number: PB0179

Antithrombotic Effects of a Novel Small Molecular Fxia Inhibitor BMS-986177/JNJ-70033093 in a Rabbit AV-Shunt Model of Thrombosis

X. Wang, Q. Li, F. Du, N. Shukla, A. Nawrocki, M. Chintala

Abstract Number: PB0219

Are the Plasma Levels Thresholds of DOAC Rationale and Appropriate for Clinical Decision-making? A Reappraisal Using Thrombin Generation Testing

J. Evrard¹, J.-M. Dogné^1,2, M. Hardy^3,4, S. Lessire³, V. Maloteau¹, L. Morimont^1,5, F. Mullier⁴, R. Siriez¹, J. Douxfils^1,5

Abstract Number: PB0236

Assessment of Four Factor Prothrombin Complex Concentrate (4F-PCC) Usage in Emergency Department Patients: A Single Center Experience

H. McRae, F. Kara, R. Baum, N. Acquisto, M. Refaai

Abstract Number: PB0234

Baseline VWF Antigen Level Is Associated with the Outcome of Immune Tolerance Induction Using pdFVIII/VWF Concentrate in Hemophilia A with Inhibitor

Z. Li¹, Z. Chen¹, X. Cheng¹, X. Wu¹, G. Li¹, Y. Zhen¹, S. Cai², M.-C. Poon³, R. Wu¹

Abstract Number: PB0214

Bisecting the Role of the C-terminal End of Antithrombin: Natural Variants due to a Frameshift at Different Secondary Structures May Exacerbate or Ameliorate a New Dominant-negative Effect

C. Bravo-Perez¹, M. Toderici¹, B. de la Morena-Barrio¹, J. Padilla¹, A. Miñano¹, A. Palomo², H. Perez-Sanchez³, J. Martinez-Menarguez⁴, J. Chambers⁵, S. Marciniak⁵, V. Vicente¹, J. Corral¹, M.E. de la Morena-Barrio¹

Abstract Number: PB0206

Characterisation and Evaluation of a Candidate Bethesda Assay Reference Reagent Developed from Recombinant, Patient-Derived FVIII Inhibitors

C. Coxon¹, J. Beavis², X. Yu³, S. Diamond³, A. Riches¹, S. Raut¹